期刊
BMJ-BRITISH MEDICAL JOURNAL
卷 334, 期 7585, 页码 120-123出版社
BMJ PUBLISHING GROUP
DOI: 10.1136/bmj.39024.487720.68
关键词
-
In October UK patients who had cardiovascular events while taking rofecoxib lost the right to fight Merck in the US for compensation. But researchers and journals can still benefit from this case if they learn from the mistakes, write Harlan Krumholz and colleagues.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据